Open Label, Single Dose, Parallel-group Study to Evaluate the PK and the Safety and Tolerability of Single Oral Doses of BI 1291583 in Trial Participants With Mild, Moderate and Severe Hepatic Impairment as Compared to Matched, Hepatically Healthy Trial Participants.
Latest Information Update: 23 Jun 2025
At a glance
- Drugs BI 1291583 (Primary)
- Indications Bronchiectasis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
Most Recent Events
- 23 Jun 2025 New trial record